SCHEMBL762107

SCHEMBL762107

CNc1c(C)cc(Br)cc1C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 2/20 0.44
AKR1C2 P52895 2/20 0.44
AKR1C1 Q04828 2/20 0.44
AKR1C4 P17516 1/20 0.44
HSD17B10 Q99714 1/20 0.43
MAPT P10636 1/20 0.41
ALDH1A1 P00352 3/20 0.41
HMGB1 P09429 1/20 0.41
CXCL12 P48061 1/20 0.41
MYC P01106 1/20 0.40
NR4A1 P22736 1/20 0.40
METAP2 P50579 2/20 0.40
KDM4E B2RXH2 1/20 0.39
GLA P06280 1/20 0.39
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
TAS1R2 Q8TE23 1/20 0.39
SORT1 Q99523 3/20 0.38
HPGD P15428 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL950710 0.83 AKR1C3 (0.55) AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10
SCHEMBL9276237 0.81 AKR1C3 (0.48) AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10
SCHEMBL5094596 0.81 METAP2 (0.57) ALDH1A1HMGB1CXCL12METAP2KDM4E
SCHEMBL22636387 0.78 ALDH1A1 (0.56) AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10
SCHEMBL4314430 0.78 ALDH1A1 (0.44) AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10
SCHEMBL29021130 0.77 HTR1D (0.41) MAPTALDH1A1KDM4ETAS1R3TAS1R1
SCHEMBL29606250 0.77 HPGD (0.44) MAPTALDH1A1TAS1R3TAS1R1TAS1R2
SCHEMBL11972812 0.77 AKR1C3 (0.47) AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10
SCHEMBL24399523 0.76 AKR1C3 (0.50) AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10
SCHEMBL1071109 0.76 AKR1C3 (0.50) AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103755681-B 3-(2,2,3,3-tetrafluoropropoxy)-pyrazole amide compound and application thereof UNIV QINGDAO SCIENCE & TECHNOLOGY 2015-04-22 CN disclosed
CN-103755681-A 3-(2,2,3,3-tetrafluoropropoxy)-pyrazole amide compound and application thereof UNIV QINGDAO SCIENCE & TECHNOLOGY 2014-04-30 CN disclosed
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
CN-101437519-A Indazole compounds ABBOTT LAB (US) 2009-05-20 CN disclosed
EP-2001480-A2 INDAZOLE COMPOUNDS Abbott Laboratories (US) 2008-12-17 EP disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
WO-2007117465-A2 INDAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 AKR1C3 482/4885AKR1C2 603/4885AKR1C1 488/4885
US-20120053345-A1 Indazole Compounds CYP3A43, CYP3A7, UGT1A1 AKR1C3 482/4885AKR1C2 603/4885AKR1C1 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.